Sign In
Buy WGS
$53.02
-0.110 (-0.207%)
At Close: Jun 03, 2026
Illumina constellation mapped read technology uncovers hard-to-see genomic insights in GeneDx pilot
09:15am, Wednesday, 15'th Oct 2025
Illumina's up-and-coming constellation innovation delivers accuracy, speed, and ease of use in trial by GeneDx Constellation outperformed orthogonal methods in identifying select difficult-to-map vari
GeneDx's Blueprint For The Next Healthcare Revolution
02:55am, Wednesday, 15'th Oct 2025
GeneDx Holdings is transforming into a global genetic software leader, leveraging its vast database and recent Fabric Genomics acquisition. WGS achieved strong Q2 results: 49% revenue growth, 71% gros
How GeneDX CEO Katherine Stueland is using AI to save lives
03:17pm, Tuesday, 14'th Oct 2025
She started her career helping launch breakthrough treatments for HIV and cancer. Today, Katherine Stueland is leading GeneDx — a genetic testing company using genomic insights to diagnose rare dise
GeneDx Appoints Dr. Mimi Lee as Chief Precision Medicine Officer
08:00am, Tuesday, 14'th Oct 2025
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx today announced Dr. Mimi Lee, MD, PhD, as Chief Precision Medicine Officer.
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx today announced its involvement in the Sunshine Genetics Act, establishing the nation's first state-backed genomic newborn screening program.
GeneDx to Launch Autism Partnership Program to Expand Access to Exome and Genome Testing, including Dedicated SHANK3 Program
08:00am, Thursday, 09'th Oct 2025
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx today announced the Autism Partnership Program to expand access to exome and genome testing in partnership with Jaguar Gene Therapy.
GeneDx to Showcase Pioneering Research Findings at American Society of Human Genetics (ASHG) Annual Meeting
08:00am, Wednesday, 08'th Oct 2025
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx today announced pioneering scientific contributions that will be presented at the American Society of Human Genetics (ASHG) Annual Meeting.
GeneDx to Report Third Quarter 2025 Financial Results on Tuesday, October 28, 2025
08:00am, Tuesday, 07'th Oct 2025
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx today announced it will release financial results for the third quarter of 2025 before the market opens on Tuesday, October 28, 2025.
GeneDx Announces First U.S. National Genomic Newborn Screening Initiative Launched with $14.4 Million NIH Award
04:01pm, Wednesday, 01'st Oct 2025
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx today announced the launch of BEACONS, the nation's first multi-state genomic newborn screening initiative.
GeneDx Appoints Lisa Gurry as Chief Business Officer to Unlock Data and Information Growth
08:00am, Tuesday, 30'th Sep 2025
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) today announced the appointment of Lisa Gurry as Chief Business Officer, effective immediately.
Gilat Receives Over $7 Million Orders to Supply Transportable SATCOM Terminals to the U.S. Army
07:06am, Tuesday, 30'th Sep 2025
Gilat Defense continues to supply WGS-certified DKET solution to strengthen mission-critical connectivity for U.S. defense operations Gilat Defense continues to supply WGS-certified DKET solution to s
GeneDx Infinity™ Pioneers a New Era of Genetic Medicine with its Introduction at the American Academy of Pediatrics National Conference
08:00am, Thursday, 25'th Sep 2025
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will introduce pediatricians to GeneDx's Infinity
3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2025
12:36pm, Thursday, 18'th Sep 2025
GeneDx, Twist Bioscience and Wave Life Sciences are emerging as key players in the fast-growing genomics and synthetic biology space.
GeneDx Appoints Visionary AI and Precision Medicine Leader Dr. Thomas Fuchs to Board of Directors
08:00am, Thursday, 18'th Sep 2025
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx Appoints Visionary AI and Precision Medicine Leader Dr. Thomas Fuchs to Board of Directors.
NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of GeneDx Holdings C
